Portal de Periódicos da CAPES

Rilmenidine

1990; Wiley; Volume: 8; Issue: 1 Linguagem: Turco

10.1111/j.1527-3466.1990.tb00429.x

1527-3466

Tony J. Verbeuren, Anh Tuan Dinh‐Xuan, Elisabeth Koenig‐Bérard, Philippe Vitou,

Pharmacological Receptor Mechanisms and Effects

Cardiovascular Drug ReviewsVolume 8, Issue 1 p. 56-70 Free to Read Rilmenidine Tony J. Verbeuren, Corresponding Author Tony J. Verbeuren Department of Cardiovascular Pharmacology, Institut de Recherches Servier, Suresnes, FranceAddress correspondence to Dr. T. J. Verbeuren at IDRS, 11 rue des Moulineaux, 92150 Suresnes, France. Address reprint requests to Dr. E. Koenig-Berard at IRIS, 22 rue Gamier, 92200 Neuilly-sur-Seine, France.Search for more papers by this authorA. Tuan Dinh Xuan, A. Tuan Dinh Xuan Laboratoire d'Explorations Fonctionnelles, Hopital Cochin, Paris, FranceSearch for more papers by this authorElisabeth Koenig-Bérard, Elisabeth Koenig-Bérard Institut de Recherches Internationales Servier, Neuilly-sur-Seine, FranceSearch for more papers by this authorPhilippe Vitou, Philippe Vitou Institut de Recherches Internationales Servier, Neuilly-sur-Seine, FranceSearch for more papers by this author Tony J. Verbeuren, Corresponding Author Tony J. Verbeuren Department of Cardiovascular Pharmacology, Institut de Recherches Servier, Suresnes, FranceAddress correspondence to Dr. T. J. Verbeuren at IDRS, 11 rue des Moulineaux, 92150 Suresnes, France. Address reprint requests to Dr. E. Koenig-Berard at IRIS, 22 rue Gamier, 92200 Neuilly-sur-Seine, France.Search for more papers by this authorA. Tuan Dinh Xuan, A. Tuan Dinh Xuan Laboratoire d'Explorations Fonctionnelles, Hopital Cochin, Paris, FranceSearch for more papers by this authorElisabeth Koenig-Bérard, Elisabeth Koenig-Bérard Institut de Recherches Internationales Servier, Neuilly-sur-Seine, FranceSearch for more papers by this authorPhilippe Vitou, Philippe Vitou Institut de Recherches Internationales Servier, Neuilly-sur-Seine, FranceSearch for more papers by this author First published: March 1990 https://doi.org/10.1111/j.1527-3466.1990.tb00429.xCitations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Ashkenazi S, Mimouni M, Laron Z, Varsano I. Asthmatic attack associated with oral clonidine test. EurJ Pediatr 1984; 142: 125. 2 Atlas D, Burstein Y. Isolation and partial purification of a clonidine-displacing endogenous brain substance. EurJ Biochem 1984; 144: 287–93. 3 Barker JL, Crayton JW, Nicoll RA. Supraoptic neurosecretory cells: adrenergic and cholinergic sensitivity. Science 1971; 171: 208–10. 4 Beau B, Mahieux F, Paraire M, Laurin S, Brisgand B, Vitou P. Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol 1988; 61: 95D–102D. 5 Bousquet P. Central antihypertensive drugs: proposals for novel concepts and therapeutical perspectives. La lettre du Pharmacologue 1989; 3: 3–10. 5a Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230: 232–6. 6 Bousquet P, Feldman J, Atlas D. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur J Pharmacol 1986; 124: 167–70. 7 Bricca G, Dontenwill M, Molines A, et al. Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 1989; 163: 373–7. 8 Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P. The imidazoline preferring receptor: binding studies in bovine, rat, and human brainstem. Eur J Pharmacol 1989; 162: 1–9. 9 Callens-El Amrani F, Paolaggi F, Swynghedauw B. Remodeling of the heart in DOCA-salt hypertensive rats by rilmenidine and propranolol. J Hypertension (in press). 10 Coupry I, Lachaud V, Podevin RA, Koenig E, Parini A. Different affinities of α2-agonists for imidazoline and α2-adrenergic receptors. Am J Hypert 1989; 2: 468–70. 11 De Divitiis O, Di Somma S, Liguori V., et al. Effort blood pressure control in the course of antihypertensive treatments. Am J Med 1989; 87(Suppl. 3C): 46S–56S. 12 Dinh Xuan AT, Regnard J, Matran R, Mantrand P, Advenier C, Lockhart A. Effects of clonidine on bronchial responses to histamine in normal and asthmatic subjects. Eur Respir J 1988; 1: 345–50. 13 Dinh Xuan AT, Matran R, Regnard J, Vitou P, Advenier C, Lockhart A. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects. Br J Clin Pharmacox 1988; 26: 703–8. 14 Dinh Xuan AT, Lockhart A. Bronchial effects of alpha-2 adrenoceptor agonists and of other antihypertensive agents in asthma. Am J Med 1989; 87(Suppl. 3C): 34S–7S. 15 Dollery CT, Davies DS, Duchier J, Pannier B, Safer ME. Dose and concentration-effect relations for rilmenidine. Am J Cardiol 1988; 61: 60D–66D. 16 Dresse A, Scuvee-Moreau J. Influence of the alpha-2 agonist oxaminozoline (S 3341) on firing rate of central noradrenergic and serotoninergic neurons in the rat. Comparison with clonidine. Arch Int Physiol Biochim 1986; 94: 99–106. 17 Dresse A, Scuvee-Moreau J, Seutin V. Action of rilmenidine on locus coeruleus and dorsal raphe cells in vivo and in vitro. Am J Cardiol 1988; 61: 32D–34D. 18 Ehrhardt JD. Gas chromatography negative ion mass spectrometric assay of 2 dicyclopropylmethyl araino-2-oxazoline (S 3341), a new antihypertensive drug. Biomed Mass Spectrom 1985; 12: 593–5. 19 Fillastre JP, Letac B, Galinier F, Le Bihan G, Schwartz J. A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988; 61: 81D–85D. 20 Fiorentini C, Guillet C, Guazzi M. Etude multicentrique italienne en double aveugle comparant la rilmenidine 1 mg et l'hydrochlorothiazide 25 mg chez 244 patients. Arch Mal Coeur Vaiss 1990; 82: 39–46. 21 Galley P, Manciet G, Hessel JL, Michel JP. Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. Am J Cardiol 1988; 61: 86D–90D. 22 Garattini S, Remuzzi G, Perico N, Tierney C. Effects of chronic administration of oxaminozoline (S 3341) on renal function and on renal prostaglandins in spontaneously hypertensive rats (SHR) [Abstract]. First International Symposium on Oxaminozoline, a novel alpha-2 agonist antihypertensive agent 1986. 23 Genissel P, Bromet N, Fourtillan JB, Mignot A, Albin H. Pharmacokinetics of rilmenidine in healthy subjects. Am J Cardiol 1988; 61: 47D–53D. 24 Ghaemmaghami F, Ibanez J, Geelen G, Vincent M, Frutoso J, Gharib C. Effects of swim-training alone and in combination with clonidine and rilmenidine on blood pressure, plasma electrolytes, vaso-pressin and renin activity in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1989; 15: 68–74. 25 Greenberg S, Wilborn WM. Effect of chronic administration of clonidine and propranolol on the myocardium of spontaneously hypertensive rats. Arch Int Pharmacodyn Ther 1982; 255: 141–61. 26 Guicheney P, Dausse JP, Meyer P. Affinités respectives du S 3341 et de la clonidine pour les récepteurs adrénergiques alpha-1 et alpha-2 du cerveau du rat. J Pharmacol (Paris) 1981; 12: 255–62. 27 Guicheney P, Dausse JP, Meyer P. Interaction du prazosin avec les membranes cardiaques. Méthode d'étude de l'action périphérique des agents alpha-adrénergiques. Arch Mal Coeur 1981; 74: 67–70. 28 Harron DWG. Antihypertensive drugs and baroreflex sensitivity: effect of rilmenidine. Am J Med 1989; 87(Suppl. 3C): 57S–62S. 29 Ibrahim MM, Tarazi RC, Dunstan HP. Orthostatic hypotension: mechanism and management. Am Heart J 1975; 90: 513–520. 30 Jarrott B, Lewis SJ, Doyle AE, Louis WJ. Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine (S 3341) on cardiovascular and behavioral parameters of spontaneously hypertensive rats. Am J Cardiol 1988; 61: 39D–44D. 31 Johnston AL, Koenig-Bérard E, Cooper TA, File SE. Comparison of the effects of clonidine, rilmenidine, and guanfacine in the holeboard and elevated plusmaze. Drug Dev Res 1988; 15: 405–14. 32 Kobinger W. Central alpha adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 1978; 81: 40. 33 Koenig-Berard E, Tierney C, Beau B, Delbarre B, Lhoste F, Labrid C. Cardiovascular and central nervous system effects of rilmenidine (S 3341) in rats. Am J Cardiol 1988; 61: 22D–31D. 34 Lachaud V, Coupry I, Podevin RA, Dausse JP, Koenig E, Parini A. Interaction of clonidine and rilmenidine with imidazoline-preferring receptors. J Hypert 1988; 6(suppl 4): S511–S513. 35 Laubie M, Poignant JC, Scuvée-Moreau J, Dabire H, Dresse A, Schmitt H. Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S 3341) an alpha-2 adrenoceptor agonist. J Pharmacol (Paris) 1985; 16: 259–78. 36 Leary WP. Renal excretory actions of antihypertensive agents; effects of rilmenidine. Am J Med 1989; 87(Suppl.3C): 63S–6S. 37 Lewis SJ, Jarrott B, Doyle AE. Rapid eye movement sleep and the associated cardiovascular changes during and after continuous 10-day infusion of clonidine in normotensive rats: comparison with lofexidine and S 3341. J Cardiovasc Pharmacol 1987; 9: 711–8. 38 Li CG and Rand MJ. Rilmenidine acts as a partial agonist at prejunctional α2-adrenoceptors in guinea pigatria. Clin Exp Pharmacol Physiol 1988; 15: 765–72. 39 Lins RL, Daelemans R, Dratwa M. Acceptability of rilmenidine and long-term surveillance of plasma concentrations in hypertensive patients with renal insufficiency. Am J Med 1989; 87(Suppl. 3C): 41S–5S. 40 Meeley MP, Ernsberger PR, Granata AR, Reis DJ. An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Lice Sci 1986; 38: 1119–26. 41 Mpoy M, Vandeleene B, Ketelslegers JM, Lambert AE. Treatment of systemic hypertension in insulintreated diabetes mellitus with rilmenidine. Am J Cardiol 1988; 61: 91D–94D. 42 Murray S, Watson D, Davies DS. Bistrifluoromethylaryl derivatives for drug analysis by gas chromatography electron capture negative ion chemical ionization mass spectrometry. Application to the measurement of (N-dicyclopropylmethyl) amino-2-oxazoline in plasma. Biomed Mass Spectrom 1985; 12: 230–7. 43 Nguyen Van Cao A, Levy B, Slama R. Noninvasive study of cardiac structure and function after rilmenidine for essential hypertension. Am J Cardiol 1988; 61: 72D–75D. 44 Ostermann G, Brisgand B, Schmitt J, Fillastre JP. Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. Am J Cardiol 1988; 61: 76D–80D. 45 Pannier B, Safar M. Effets de la rilmenidine sur les paramètres artériels dans l'hypertension artérielle essentielle. Arch Mal Coeur Vaiss 1990; 82: 47–51. 46 Roach AG, Doxey JL, Stracham DA, Cavero I. Sleeping time evoked by alpha adrenoceptor agonists in two day old chicks: an experimental model to evaluate full and partial agonists at central alpha 2 adrenoceptors. J Pharmacol Exp Ther 1983; 227: 421–8. 47 Singlas E, Ehrhardt JD, Zech P, Pozet N, Genissel P. Pharmacokinetics of rilmenidine. Am J Cardiol 1988; 61: 54D–59D. 48 Tierney C, Nadaud D, Koenig-Bérard E, Stinus L. Effects of two alpha 2 agonists, rilmenidine and clonidine, on the morphine withdrawal syndrome and their potential addictive properties in rats. Am J Cardiol 1988; 61: 35D–38D. 49 Timmermans PBMWM, Schoop AMC, Kwa HY, Van Zwieten PA. Characterization of alpha-adreno-ceptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine. Eur J Pharmacol 1981; 70: 7–15. 50 UK working party on rilmenidine. Rilmenidine in mild to moderate essential hypertension: a double blind, randomised, parallel group, multicentre comparison with methyldopa in 157 patients. Current Ther Res 1990 (in press). 51 Ung HL, Girault J, Lefebvre MA, Mignot A, Fourtillan JB. Quantitative analysis of S 3341 in human plasma and urine by combined gaschromatography-negati ve ion chemical ionisation massspectrometry: 15 month interday precision and accuracy validation. Biomed Mass Spectrom 1987; 14: 289–93. 52 Valet P, Tran MA, Damase-Michel C., et al. Rilmenidine (S 3341) and the sympatho-adrenal system: adrenoreceptors, plasma and adrenal catecholamines in dogs. J Auton Pharmac 1988; 8: 319–26. 53 Van Zwieten PA, Thoolen MJMC, Jonkman FAM, Wilffert B, De Jong A, Timmermans PBMWM. Central and peripheral effects of S 3341 (N-dicyclopropylmethyl)-amino-2-oxazoline in animal models. Arch Int Pharmacodyn Ther 1986; 279: 130–49. 54 Van Zwieten PA. Pharmacology of the alpha-2 adrenoceptor agonist rilmenidine. Am J Cardiol 1988; 61: 6D–14D. 55 Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Herman AG. Effect of the amino-oxazoline derivative S 3341 on pre- and postjunctional alpha-adrenoceptors in isolated blood vessels. Arch Int Pharmacodyn Ther 1986; 284: 38–52. 56 Verbeuren TJ, Koenig-Berard E, Jordaens FH, et al. Interaction of rilmenidine and clonidine with pre- and postjunctional alpha-adrenoceptors in rat and rabbit blood vessels and in rat kidneys. Arch Int Pharmacodyn Ther 1989; 300: 114–39. 57 Waelsch H. The turnover of components of the developing brain: the blood brain barrier. In: H Waelsch, ed. Biochemistry of the developing nervous system. New York : Academic Press. 1955: 1987. 58 Zannad F, Aliot E, Florentin J, Saulnier JP, Gilgenkrantz JM. Hemodynamic and electrophysiologic effects of a new alpha-2 adrenoceptor agonist, rilmenidine, for systemic hypertension. Am J Cardiol 1988; 61: 67D–71D. Citing Literature Volume8, Issue1March 1990Pages 56-70 ReferencesRelatedInformation